SCHEMBL2419477

SCHEMBL2419477

CCCCCCCC(=O)C(O)[C@H]1O[C@@H](n2cc(F)c(=O)[nH]c2=O)C[C@@]1(O)C(=O)CCCCCCC

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
TK2 O00142 3/20 0.38
SQOR Q9Y6N5 2/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
MAPK3 P27361 1/20 0.38
ASAH1 Q13510 1/20 0.38
MAPT P10636 2/20 0.36
ESR1 P03372 1/20 0.36
TSHR P16473 1/20 0.35
PMP22 Q01453 1/20 0.35
HBB P68871 1/20 0.35
PLA2G1B P04054 1/20 0.34
ATG4B Q9Y4P1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10428773 1.00 LMNA (0.39) LMNASMN1; SMN2TK2SQORCYP3A4
SCHEMBL3185225 1.00 LMNA (0.39) LMNASMN1; SMN2TK2SQORCYP3A4
SCHEMBL3179329 1.00 LMNA (0.39) LMNASMN1; SMN2TK2SQORCYP3A4
SCHEMBL3183300 1.00 LMNA (0.39) LMNASMN1; SMN2TK2SQORCYP3A4
SCHEMBL9747028 1.00 LMNA (0.39) LMNASMN1; SMN2TK2SQORCYP3A4
SCHEMBL9744350 0.99 LMNA (0.40) LMNASMN1; SMN2TK2SQORCYP3A4
SCHEMBL11020536 0.92 LMNA (0.40) LMNASMN1; SMN2TK2MAPTESR1
SCHEMBL11022379 0.92 LMNA (0.40) LMNASMN1; SMN2TK2MAPTESR1
SCHEMBL10458148 0.91 LMNA (0.41) LMNASMN1; SMN2TK2MAPTESR1
SCHEMBL9745084 0.90 SQOR (0.44) SMN1; SMN2TK2SQORASAH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3133087-A1 ASSAY OF CYTOKINES ASSOCIATED WITH MSRV/HERV-W bioMérieux (FR) 2017-02-22 EP disclosed
EP-1709082-B1 COMPOSITION FOR TREATING PATHOLOGY ASSOCIATED WITH MSRV/HERV-W BIOMERIEUX SA (FR) 2014-03-12 EP disclosed
EP-2365002-A2 Composition for treating a pathology associated with MSRV/HERV-W bioMérieux (FR) 2011-09-14 EP disclosed
US-7666420-B2 Composition for treating pathology associated with MSRV/HERV-W BIOMERIEUX (FR) 2010-02-23 US disclosed
US-20080038279-A1 Composition For Treating Pathology Associated With Msrv/Herv-W BIOMERIEUX (FR) 2008-02-14 US disclosed
EP-0227844-B1 ANTIVIRAL DRUG TEIJIN LIMITED (JP) 1992-05-13 EP disclosed
EP-0214299-B1 PREPARATION OF 5-FLUORO-2'-DEOXYURIDINE ESTERS FOR INTRAARTERIAL ADMINISTRATION TEIJIN LIMITED (JP) 1992-05-13 EP disclosed
US-5013828-A Fluorinating 2'-deoxyuridine with fluorine gas, fatty acid salt present, acylation with acid anhydride or halide CENTRAL GLASS COMPANY, LIMITED (JP) 1991-05-07 US disclosed
US-4943564-A Intraarterial injection pharmaceuticals of 5-fluoro-2'-deoxyuridine esters TEIJIN LIMITED (JP) 1990-07-24 US disclosed
US-4868162-A 5-HALO-2*-DEOXYURIDINE DERIVATIVE TEIJIN LIMITED (JP) 1989-09-19 US disclosed
US-4757139-A 5-fluoro-2'-deoxyuridine derivative, processes for preparing same and antitumor composition containing the same TEIJIN LIMITED (JP) 1988-07-12 US disclosed
EP-0227844-A1 ANTIVIRAL DRUG TEIJIN LIMITED (JP) 1987-07-08 EP disclosed
EP-0214299-A1 PREPARATION OF 5-FLUORO-2'-DEOXYURIDINE ESTERS FOR INTRAARTERIAL ADMINISTRATION TEIJIN LIMITED (JP) 1987-03-18 EP disclosed
EP-0151189-A1 ANTINEOPLASTIC AGENT TEIJIN LIMITED (JP) 1985-08-14 EP disclosed